433 related articles for article (PubMed ID: 30557443)
1. Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse.
Murphy SM; McCollister KE; Leff JA; Yang X; Jeng PJ; Lee JD; Nunes EV; Novo P; Rotrosen J; Schackman BR
Ann Intern Med; 2019 Jan; 170(2):90-98. PubMed ID: 30557443
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.
Schackman BR; Leff JA; Polsky D; Moore BA; Fiellin DA
J Gen Intern Med; 2012 Jun; 27(6):669-76. PubMed ID: 22215271
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Treatments for Opioid Use Disorder.
Fairley M; Humphreys K; Joyce VR; Bounthavong M; Trafton J; Combs A; Oliva EM; Goldhaber-Fiebert JD; Asch SM; Brandeau ML; Owens DK
JAMA Psychiatry; 2021 Jul; 78(7):767-777. PubMed ID: 33787832
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
Tanum L; Solli KK; Latif ZE; Benth JŠ; Opheim A; Sharma-Haase K; Krajci P; Kunøe N
JAMA Psychiatry; 2017 Dec; 74(12):1197-1205. PubMed ID: 29049469
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence.
Jackson H; Mandell K; Johnson K; Chatterjee D; Vanness DJ
Subst Abus; 2015; 36(2):226-31. PubMed ID: 25775099
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder.
Murphy SM; Polsky D; Lee JD; Friedmann PD; Kinlock TW; Nunes EV; Bonnie RJ; Gordon M; Chen DT; Boney TY; O'Brien CP
Addiction; 2017 Aug; 112(8):1440-1450. PubMed ID: 28239984
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial.
Polsky D; Glick HA; Yang J; Subramaniam GA; Poole SA; Woody GE
Addiction; 2010 Sep; 105(9):1616-24. PubMed ID: 20626379
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis.
Murphy SM; Jeng PJ; McCollister KE; Leff JA; Jalali A; Shulman M; Lee JD; Nunes EV; Novo P; Rotrosen J; Schackman BR
Addiction; 2021 Dec; 116(12):3444-3453. PubMed ID: 33950535
[TBL] [Abstract][Full Text] [Related]
9. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.
Weiss RD; Potter JS; Fiellin DA; Byrne M; Connery HS; Dickinson W; Gardin J; Griffin ML; Gourevitch MN; Haller DL; Hasson AL; Huang Z; Jacobs P; Kosinski AS; Lindblad R; McCance-Katz EF; Provost SE; Selzer J; Somoza EC; Sonne SC; Ling W
Arch Gen Psychiatry; 2011 Dec; 68(12):1238-46. PubMed ID: 22065255
[TBL] [Abstract][Full Text] [Related]
10. Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment.
Nunes EV; Scodes JM; Pavlicova M; Lee JD; Novo P; Campbell ANC; Rotrosen J
Am J Psychiatry; 2021 Jul; 178(7):660-671. PubMed ID: 34170188
[TBL] [Abstract][Full Text] [Related]
11. NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.
Lee JD; Nunes EV; Mpa PN; Bailey GL; Brigham GS; Cohen AJ; Fishman M; Ling W; Lindblad R; Shmueli-Blumberg D; Stablein D; May J; Salazar D; Liu D; Rotrosen J
Contemp Clin Trials; 2016 Sep; 50():253-64. PubMed ID: 27521809
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of subdermal implantable buprenorphine versus sublingual buprenorphine to treat opioid use disorder.
Carter JA; Dammerman R; Frost M
J Med Econ; 2017 Aug; 20(8):893-901. PubMed ID: 28604141
[TBL] [Abstract][Full Text] [Related]
13. Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study.
Kenworthy J; Yi Y; Wright A; Brown J; Maria Madrigal A; Dunlop WCN
J Med Econ; 2017 Jul; 20(7):740-748. PubMed ID: 28489467
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of flexible take-home buprenorphine-naloxone versus methadone for treatment of prescription-type opioid use disorder.
Enns B; Krebs E; Whitehurst DGT; Jutras-Aswad D; Le Foll B; Socias ME; Nosyk B;
Drug Alcohol Depend; 2023 Jun; 247():109893. PubMed ID: 37120920
[TBL] [Abstract][Full Text] [Related]
15. Opioid drug utilization and cost outcomes associated with the use of buprenorphine-naloxone in patients with a history of prescription opioid use.
Kaur AD; McQueen A; Jan S
J Manag Care Pharm; 2008 Mar; 14(2):186-94. PubMed ID: 18331120
[TBL] [Abstract][Full Text] [Related]
16. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
[No Abstract] [Full Text] [Related]
17. No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: A 3-month randomized study and 9-month open-treatment follow-up study.
Latif ZE; Solli KK; Opheim A; Kunoe N; Benth JŠ; Krajci P; Sharma-Haase K; Tanum L
Am J Addict; 2019 Feb; 28(2):77-85. PubMed ID: 30701613
[TBL] [Abstract][Full Text] [Related]
18. Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial.
Nunes EV; Comer SD; Lofwall MR; Walsh SL; Peterson S; Tiberg F; Hjelmstrom P; Budilovsky-Kelley NR
JAMA Netw Open; 2024 Jun; 7(6):e2417377. PubMed ID: 38916892
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.
Sigmon SC; Dunn KE; Saulsgiver K; Patrick ME; Badger GJ; Heil SH; Brooklyn JR; Higgins ST
JAMA Psychiatry; 2013 Dec; 70(12):1347-54. PubMed ID: 24153411
[TBL] [Abstract][Full Text] [Related]
20. Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trial.
Shulman M; Provost S; Ohrtman K; Novo P; Meyers-Ohki S; Van Veldhuisen P; Oden N; Otterstatter M; Bailey GL; Liu D; Rotrosen J; Nunes EV; Weiss RD
Contemp Clin Trials; 2024 Jul; 142():107543. PubMed ID: 38657730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
